NASDAQ:MEDP - Medpace Stock Price, Forecast & News

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) issued its quarterly earnings data on Tuesday, October, 29th. The company reported $0.71 earnings per share for the quarter, hitting the consensus estimate of $0.71. The company had revenue of $216.20 million for the quarter, compared to analysts' expectations of $217.14 million. Medpace had a net margin of 11.35% and a return on equity of 17.06%. Medpace's revenue for the quarter was up 20.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Medpace.

Medpace will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace updated its FY19 earnings guidance on Monday, October, 28th. The company provided EPS guidance of $2.85-2.97 for the period, compared to the Thomson Reuters consensus estimate of $2.91. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $857.27 million.

4 brokers have issued 1-year target prices for Medpace's stock. Their forecasts range from $62.00 to $85.00. On average, they expect Medpace's share price to reach $74.67 in the next twelve months. This suggests that the stock has a possible downside of 17.9%. View Analyst Price Targets for Medpace.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Media coverage about MEDP stock has trended positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Medpace earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Medpace.

Medpace saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 2,460,000 shares, an increase of 5.1% from the November 28th total of 2,340,000 shares. Based on an average trading volume of 307,200 shares, the short-interest ratio is currently 8.0 days. Currently, 8.9% of the shares of the stock are sold short. View Medpace's Current Options Chain.

Some companies that are related to Medpace include EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Paycom Software (PAYC), Adobe (ADBE), Paypal (PYPL), Arista Networks (ANET), Veeva Systems (VEEV), Cyberark Software (CYBR) and Fortinet (FTNT).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by many different of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.52%), Scout Investments Inc. (0.27%), McGuire Investment Group LLC (0.11%), State of Alaska Department of Revenue (0.06%), First National Bank of Omaha (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Assenagon Asset Management S.A., Tributary Capital Management LLC, Scout Investments Inc., Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was bought by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC, Vigilant Capital Management LLC and First National Bank of Omaha. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $90.95.

Medpace has a market capitalization of $3.28 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]